ADVERTISEMENT
  • News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Saturday, December 9, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Health&Beauty

Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer

The FINANCIAL by The FINANCIAL
July 26, 2016
in Health&Beauty
Reading Time: 2 mins read
A A
0
Largest genome-wide study of lung cancer susceptibility conducted
Share on FacebookShare on Twitter

The FINANCIAL — Bristol-Myers Squibb Company today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC).

Opdivo is a human antibody designed to alleviate immune suppression. JNJ-64041757 is designed to induce the local recruitment and activation of innate and adaptive effector cells and expansion of mesothelin-specific T cells. The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of these agents in NSCLC patients.

“We are excited to collaborate with Janssen as we explore how the emerging science of antigen-presentation therapeutics, in combination with Opdivo, can potentially provide a new treatment approach for patients with lung cancer,” said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.

RelatedPosts

The Washington State revokes, suspends licenses ანდ registrations of health care providers

There were an estimated 39.0 million people living with HIV at the end of 2022, mainly in Africa

Women in England to receive contraceptive pills at pharmacies

Drowsy Driving Is a Factor in 21% of Fatal Crashes. Why Don’t We Talk About It More?

Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world in July 2014, and currently has regulatory approval in 54 countries including the United States, Japan, and in the European Union, according to Bristol-Myers Squibb.

JNJ-64041757 (previously referred to as ADU-214) is an antigen-presentation therapeutic, based on Live Attenuated Double-Deleted (LADD) Listeria monocytogenes strains engineered to induce an immune response against NSCLC tumors. It is currently in Phase 1 clinical development for lung cancer. Opdivo is indicated for the treatment of patients with NSCLC with progression on or after platinum-based chemotherapy.

Bristol-Myers Squibb & Immuno-Oncology: Advancing Oncology Research

At Bristol-Myers Squibb, we have a vision for the future of cancer care that is focused on Immuno-Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer.

We have a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by our scientists. Our ongoing Immuno-Oncology clinical program is looking at broad patient populations, across multiple solid tumors and hematologic malignancies, and lines of therapy and histologies, with the intent of powering our trials for overall survival and other important measures like durability of response. We pioneered the research leading to the first regulatory approval for the combination of two Immuno-Oncology agents and continue to study the role of combinations in cancer.

We are also investigating other immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO and LAG-3. These pathways may lead to potential new treatment options – in combination or monotherapy – to help patients fight different types of cancers.

Our collaboration with academia, as well as small and large biotech and pharmaceutical companies, to research the potential of Immuno-Oncology and non-Immuno-Oncology combinations helps achieve our goal of providing new treatment options in clinical practice.

At Bristol-Myers Squibb, we are committed to changing survival expectations in hard-to-treat cancers and the way patients live with cancer.

 

ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Related Posts

The Washington State revokes, suspends licenses ანდ registrations of health care providers
Health&Beauty

The Washington State revokes, suspends licenses ანდ registrations of health care providers

by The FINANCIAL
December 3, 2023
0

OLYMPIA -- The Washington State Department of Health has revoked or suspended the licenses, certifications, or registrations of the following...

Read more
HIV Diagnoses at Alarmingly High Levels in the European Region Despite Progress in EU/EEA

There were an estimated 39.0 million people living with HIV at the end of 2022, mainly in Africa

November 30, 2023
Women in England to receive contraceptive pills at pharmacies

Women in England to receive contraceptive pills at pharmacies

November 18, 2023
Drowsy Driving Is a Factor in 21% of Fatal Crashes. Why Don’t We Talk About It More?

Drowsy Driving Is a Factor in 21% of Fatal Crashes. Why Don’t We Talk About It More?

November 17, 2023
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Jeff Schwartz on Emergence and Evolution of Private Debt Markets

Jeff Schwartz on Emergence and Evolution of Private Debt Markets

October 18, 2023
EasyJet to fly to London from Stockholm Arlanda

The London Diplomatic List, Addresses, Contacts & Working Hours

January 23, 2023
mobile-banking.jpg

The experts at Symple Lending discuss how rising interest rates are make paying down credit cards more difficult.

September 6, 2023
Find Social Security Number by Name Free

Find Social Security Number by Name Free

November 23, 2022
The Washington State revokes, suspends licenses ანდ registrations of health care providers

The Washington State revokes, suspends licenses ანდ registrations of health care providers

December 3, 2023
President of Asian Development Bank (ADB) met with Tegeta Holding representatives

President of Asian Development Bank (ADB) met with Tegeta Holding representatives

December 8, 2023
batumi_port_barry_kent.jpg

FactCheck : In 2019, the Georgian Dream presented a car project …

December 6, 2023
Is gold a good investment, and how to gain exposure?

Is gold a good investment, and how to gain exposure?

December 6, 2023
EU produced 14.7 million bicycles in 2022

The future of mobility

December 6, 2023
putinface.jpg

Russia is diminished in the eyes of the international community through its own actions: UK statement to the OSCE

December 6, 2023

Popular Last 24h

  • Jeff Schwartz on Emergence and Evolution of Private Debt Markets

    Jeff Schwartz on Emergence and Evolution of Private Debt Markets

    752 shares
    Share 301 Tweet 188
  • Find Social Security Number by Name Free

    2037 shares
    Share 814 Tweet 509
  • President of Asian Development Bank (ADB) met with Tegeta Holding representatives

    13 shares
    Share 5 Tweet 3
  • Alejandro Betancourt López Credits Social Media With the Success of Hawkers

    45 shares
    Share 416 Tweet 260
  • The London Diplomatic List, Addresses, Contacts & Working Hours

    1667 shares
    Share 667 Tweet 417
  • Television personalities sentenced to years in federal prison for fraud and tax evasion

    75 shares
    Share 30 Tweet 19
  • The future of mobility

    18 shares
    Share 7 Tweet 5

LATEST POSTS

President of Asian Development Bank (ADB) met with Tegeta Holding representatives

President of Asian Development Bank (ADB) met with Tegeta Holding representatives

December 8, 2023
batumi_port_barry_kent.jpg

FactCheck : In 2019, the Georgian Dream presented a car project …

December 6, 2023
Is gold a good investment, and how to gain exposure?

Is gold a good investment, and how to gain exposure?

December 6, 2023
EU produced 14.7 million bicycles in 2022

The future of mobility

December 6, 2023
putinface.jpg

Russia is diminished in the eyes of the international community through its own actions: UK statement to the OSCE

December 6, 2023
Smart Capital Group funds presenting Nodar Dumbadze Anniversary books

Smart Capital Group funds presenting Nodar Dumbadze Anniversary books

December 4, 2023
Decline in HIV transmission in in UK but progress slow in women

Decline in HIV transmission in in UK but progress slow in women

December 3, 2023
Agriculture & forestry energy consumption stable

Agriculture & forestry energy consumption stable

December 3, 2023
FAO: “Milk Production in Georgia is an Attractive Niche for Investing In” 

Which regions are focused on cereals and milk production?

December 3, 2023
Tourism peak months differ across EU regions

Tourism peak months differ across EU regions

December 3, 2023

LATEST INTERVIEWS

Lighting the path for sustainability in Georgia

Lighting the path for sustainability in Georgia

by The FINANCIAL
August 14, 2023
0

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

by The FINANCIAL
July 12, 2023
0

“EU membership might attract European banks and other financial institutions to enter Georgia”

“EU membership might attract European banks and other financial institutions to enter Georgia”

by The FINANCIAL
May 15, 2023
0

Main risks facing banks in 2023

Main risks facing banks in 2023

by The FINANCIAL
May 15, 2023
0

‘Russia cannot be treated as a reasonable and reliable trade partner

‘Russia cannot be treated as a reasonable and reliable trade partner

by The FINANCIAL
February 13, 2023
0

We should increase our joint efforts to assist the growing tech sector here in Georgia

We should increase our joint efforts to assist the growing tech sector here in Georgia

by The FINANCIAL
February 13, 2023
0

‘Georgia has much to offer to UK investors

‘Georgia has much to offer to UK investors

by The FINANCIAL
February 13, 2023
0

‘The best way for the Georgian economy to prosper is to join the EU

‘The best way for the Georgian economy to prosper is to join the EU

by The FINANCIAL
February 13, 2023
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.